He has in-depth scientific knowledge in solid tumors, a wealth of clinical experience and expertise in hematological malignancies and stem cell transplantation.
BETHESDA, MD, February 22, 2024 /24-7PressRelease/ — Han Myint, MD, FACP, FRCP, FRCPATH, has been included in Marquis Who’s Who. As in all Marquis Who’s Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Drawing on more than 30 years of health care experience, in academia and industry, Dr. Myint, Professor of Hematology and Medicine, has thrived as the Chief Medical Officer (CMO) of NextCure, Inc. since 2021. In this capacity, he is leading clinical development of novel therapies targeting tumor microenvironment, immune cells and cell of origin in various solid tumors and hematological malignancies. He has in-depth scientific knowledge in solid tumors, a wealth of clinical experience and expertise in hematological malignancies and stem cell transplantation.
Prior to his CMO roles, he was Vice President of Global Medical Affairs and the Myeloid Diseases Lead at Celgene Corporation. He played a central role in securing the U.S. Food and Drug Administration’s approval for several treatments for different myeloid disorders, successful launches of those products and high-impact publications. Prior to joining the biopharma industry, Dr. Myint practiced medicine specializing in hematological oncology and conducted clinical and laboratory research at multiple prestigious academic institutions in the UK and USA. Dr. Myint, previously obtained success as the founder and Director of the Hematological Malignancies and Stem Cell Transplant Program at the University of Colorado Denver which is widely recognized among the world’s leading stem cell transplantation centers. Alongside his primary professional responsibilities, Dr. Myint had additionally excelled as a board member of the Leukemia and Lymphoma Society, Denver Chapter as well as the Bonfil Blood Center.
A fellow of the American College of Physicians, Dr. Myint has been distinguished as an emeritus member of the American Society of Clinical Oncology and the American Society of Hematology. Likewise, he has also been distinguished as a fellow of the Royal College of Physicians of Edinburgh, the Royal College of Physicians and Surgeons of Glasgow and the Royal College of Pathologists of United Kingdom. Dr. Myint attributes a great deal of his success to the influence of his mother, who enjoyed a prosperous career as a teacher before succumbing to breast cancer, which eventually inspired him to build an expertise in oncology. In the coming years, he intends to continue to play an instrumental role in the discovery of novel therapies.
About Marquis Who’s Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who’s Who in America®, Marquis Who’s Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who’s Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who’s Who® website at www.marquiswhoswho.com.
# # #
